Cobenfy is the first drug to treat the disease that targets the brain's cholinergic receptors


Washington: The US Food and Drug Administration has approved a new drug for adults with schizophrenia.
The drug, commonly known as Cobenfy, is the first drug to treat the disease that targets the brain's cholinergic receptors, rather than the dopamine receptors that are the traditional focus of treatment.
“Schizophrenia is the leading cause of disability worldwide,” said Dr. Tiffany Farshion in the Institute's Department of Neuroscience.
He stated the drug represents the first new approach to treating schizophrenia. It offers a new alternative to the antipsychotic drugs that have previously been prescribed to people with schizophrenia.
It is pertinent to note that schizophrenia is a severe, chronic mental illness that often impairs a person's quality of life.
OGRA hikes kerosene oil price
- 9 hours ago
FIA cracks down on illegal migration: 13 caught en route to Iran
- 11 hours ago
.jpg&w=3840&q=75)
Twelve killed in Malaysia landslides after week-long downpour
- 5 hours ago
Wego expands presence in Pakistan, bring more travel choices to local travelers
- 8 hours ago
India says trade talks with US were ‘positive’
- 7 hours ago
Cinema legend Robert Redford dies at 89
- 9 hours ago
First ODI: Sidra Ameen’s ton helps Pakistan women set South Africa 256-run target
- 7 hours ago
Asia Cup T20: Bangladesh defeat Afghanistan by 8 runs
- 5 hours ago
Kazakhstan bans forced marriages and bride kidnapping
- 10 hours ago
Luxembourg announces intention to recognize Palestinian state
- 7 hours ago

At least 50 killed after refugee boat catches fire off Libyan coast
- 8 hours ago

Lahore police arrest man for sexually assaulting stepdaughter
- 12 hours ago